What is Pegfilgrastim-bmez Subcutaneous
Pegfilgrastim-bmez subcutaneous is a prescription medication used to decrease the risk of infection in people receiving chemotherapy that can weaken the immune system. Pegfilgrastim-bmez subcutaneous is also used to increase the white blood cell count in people with a low white blood cell count due to cancer, bone marrow transplant, or other conditions. Pegfilgrastim-bmez subcutaneous is a man-made form of a protein that helps the body make white blood cells.
Pegfilgrastim-bmez subcutaneous is given as an injection under the skin (subcutaneous). It is usually given once a day.
Benefits of Pegfilgrastim-bmez Subcutaneous
and Its Uses.
Pegfilgrastim-bmez subcutaneous is a synthetic form of granulocyte colony-stimulating factor (G-CSF) that is used to stimulate the growth of white blood cells in the body. It is a man-made form of a naturally occurring protein in the body that helps the bone marrow produce white blood cells. Pegfilgrastim-bmez subcutaneous is used to prevent or treat low white blood cell counts (neutropenia) caused by cancer chemotherapy. It is also used to improve survival rates after a bone marrow transplant.
Pegfilgrastim-bmez subcutaneous is given as a shot under the skin (subcutaneous injection).
Pegfilgrastim-bmez subcutaneous is available as a single-use vial that is pre-mixed with a sterile liquid.
Side Effects and Dosage of Pegfilgrastim-bmez Subcutaneous
Pegfilgrastim-bmez is a recombinant human granulocyte colony-stimulating factor (G-CSF) indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy. Pegfilgrastim-bmez is supplied as a sterile, white to off-white, lyophilized powder for subcutaneous injection after reconstitution with sterile water for injection.
The recommended dosage of pegfilgrastim-bmez is 6 mg/kg administered subcutaneously once a day. Dosage adjustments may be necessary in patients with renal impairment.
The recommended dosage of pegfilgrastim-bmez is 6 mg/kg administered subcutaneously once a day. Dosage adjustments may be necessary in patients with renal impairment. Pegfilgrastim-bmez should be administered subcutaneously at the same time each day.